Abiopharma

🔍 JACOBS CINDY (Executive)

Company: ACHIEVE LIFE SCIENCES, INC. (ACHV)

Report Date: 2025-09-04

Detailed Transactions and Holdings:

• Acquired 110,000 shares of Common Stock (Direct)
  Date: 2025-09-04 | Code: M | equity_swap_involved: false | shares_owned_after: 143,214.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 27,629 shares of Common Stock at $2.77 per share (Direct)
  Date: 2025-09-04 | Code: S | equity_swap_involved: false | shares_owned_after: 115,585.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Sold 84,000 shares of Performance Restricted Stock Unit (PRSU) (Derivative)
  Date: 2025-09-04 | Code: M | Expires: 2028-01-22 | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F4, F5, F6
• Sold 26,000 shares of Performance Restricted Stock Unit (PRSU) (Derivative)
  Date: 2025-09-04 | Code: M | Expires: 2035-01-28 | equity_swap_involved: false | shares_owned_after: 104,000.00 | transaction_form_type: 4 | Footnotes: F7, F5, F8

Footnotes:

• F1: Represents shares of common stock acquired upon settlement of the performance restricted stock units ("PRSUs") listed in Table II.
• F2: Represents shares of common stock that have been sold by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the PRSUs.
• F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.68 to $2.88 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F4: Represents PRSUs previously reported on January 24, 2024 that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors.
• F5: Each PRSU represents a contingent right to receive one share of the issuer's common stock at settlement.
• F6: Pursuant to the terms of the award agreement governing the PRSU, the total number of shares underlying the PRSU vest on the achievement of one of certain milestones.
• F7: Represents PRSUs previously reported on January 30, 2025 that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors.
• F8: Pursuant to the terms of the award agreement governing the PRSU, the number of underlying shares of the Issuer's common stock that may ultimately vest ranges from 0% to 100% of the number of the PRSUs initially granted, subject to certain milestones being met during the measurement period.